Classes of Antiparasitic Drugs and Mechanisms

Antiparasitic drugs are conventionally grouped by the kind of parasite they target into antiprotozoal agents, anthelmintics, and ectoparasiticides, with antimalarials often treated as a major subgroup of antiprotozoals. Within each group, drugs are further organised into chemical classes whose members tend to share a mechanism of action, so the classification doubles as a map of how the drugs work.

Definition

Classes of antiparasitic drugs are groupings of agents defined by the parasite group they treat and by shared chemistry and mechanism of action, such as the 4-aminoquinolines, the artemisinins, the nitroimidazoles, the benzimidazoles, the macrocyclic lactones, and the tetrahydropyrimidines.

Scope

This topic surveys the principal classes of antiparasitic drugs and the targets they exploit, organised so that classification and mechanism are seen together. It covers antimalarials, broader antiprotozoals, anthelmintics, and ectoparasiticides at the level of class and mechanism. It is a reference overview and is not prescribing guidance.

Core questions

• How are antiparasitic drugs grouped by target organism and by chemical class?
• What mechanism of action characterises each major class?
• Why do drugs in the same chemical class tend to share mechanisms and resistance patterns?
• How do antimalarials relate to the broader antiprotozoal classes?

Key concepts

• Antiprotozoal agents
• Antimalarials (4-aminoquinolines, artemisinins, antifolates)
• Anthelmintics (benzimidazoles, macrocyclic lactones, tetrahydropyrimidines)
• Ectoparasiticides
• Nitroimidazoles and nitroheterocyclic prodrugs
• Class-shared mechanism and cross-resistance

Mechanisms

Drug classes map onto mechanisms. Among antimalarials, the 4-aminoquinolines (e.g. chloroquine) interfere with the parasite's detoxification of haem released during haemoglobin digestion; the artemisinins are activated by haem iron to generate reactive intermediates that damage parasite proteins and membranes; and the antifolates block folate synthesis. Among antiprotozoals, the nitroimidazoles and other nitroheterocyclic prodrugs are reduced inside the parasite to reactive species that damage DNA. Among anthelmintics, the benzimidazoles bind parasite beta-tubulin to block microtubule function, the macrocyclic lactones open glutamate-gated chloride channels to paralyse the worm, and the tetrahydropyrimidines act as cholinergic agonists causing spastic paralysis. Because mechanism follows chemistry, members of a class commonly share both their target and the resistance mutations that defeat them.

Clinical relevance

Knowing the class of an antiparasitic drug predicts its likely mechanism, spectrum, and resistance liabilities, which is why classification underlies treatment guidelines and resistance surveillance. This entry organises drug classes for educational reference and is not a basis for selecting or dosing any drug for an individual patient.

Epidemiology

The classes outlined here are deployed against the world's major parasitic diseases: antimalarials in endemic malaria zones, antiprotozoals against leishmaniasis and trypanosomiasis, and anthelmintics in mass drug administration for soil-transmitted helminths and schistosomiasis. The narrowness of available classes means that resistance within a class can threaten control programmes broadly.

History

The earliest class was the cinchona alkaloids (quinine), followed by synthetic 4-aminoquinolines such as chloroquine in the mid-twentieth century. Benzimidazoles and the avermectin macrocyclic lactones transformed anthelmintic therapy from the 1960s-1980s, and artemisinin combination therapies became the antimalarial standard as chloroquine resistance spread. Drug discovery has since moved between target-based and phenotypic (whole-organism) screening approaches.

Debates

Target-based versus phenotypic screening for new classes

Whether new antiparasitic classes are best found by designing against a defined molecular target or by screening whole parasites for any killing activity remains contested, because eukaryotic parasites have few validated, druggable, parasite-unique targets.

Key figures

• Tu Youyou
• Satoshi Omura
• William C. Campbell
• Nicholas J. White

Seminal works

• geary-2010
• white-2014

Frequently asked questions

What are the broad groups of antiparasitic drugs?

They are usually divided by target organism into antiprotozoal agents (including antimalarials), anthelmintics (against worms), and ectoparasiticides (against external parasites such as mites and lice).

Why does knowing a drug's class matter?

Drugs in the same chemical class usually share a mechanism of action and therefore a similar spectrum and similar resistance patterns, so the class predicts much about how a drug behaves.